5 questions answered from cited research · Plain language
GLP-1 receptor agonists reduce major adverse limb events (MALE) and cardiovascular risks in people with type 2 diabetes and peripheral artery disease, based on meta-analyses.
Read the full answer →Incretin analogues (GLP-1 RAs) reduce cardiovascular risk in PAD by improving walking distance, lowering inflammation, and decreasing heart attack and stroke events.
Read the full answer →Yes, GLP-1 receptor agonists (liraglutide, semaglutide) improve walking distance in people with type 2 diabetes and peripheral artery disease, based on a 2025 meta-analysis of randomized trials.
Read the full answer →Yes, tirzepatide may reduce major adverse limb events and cardiovascular risks in people with PAD, but direct trial data are still limited.
Read the full answer →Yes, GLP-1 receptor agonists reduce major limb events in patients with type 2 diabetes and peripheral artery disease, with a 27% lower risk shown in a 2026 meta-analysis.
Read the full answer →